Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Tibolone and Escitalopram in Perimenopausal Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Females who are currently physically well and between 45 and 55 years of age~* Current DSM-IV diagnosis of depression disorder~* Able to give informed consent~* Perimenopausal as determined by symptom profile on the Stages of Reproductive Aging Workshop and gonadal hormonal profile~Exclusion Criteria:~* Known abnormalities in the hypothalamic-pituitary gonadal axis, thyroid dysfunction, central nervous system tumours, active or past history of a venous thromboembolic event, breast pathology, undiagnosed vaginal bleeding or abnormal Pap smear results in the previous 2 years.~* Patients with any significant unstable medical illness such as epilepsy and diabetes or known active cardiac, renal or liver disease; or the presence of illness causing immobilisation.~* Patients receiving treatment for depression including antidepressant medications, electroconvulsive therapy (ECT) / Transcranial Magnetic Stimulation (TMS), formal psychotherapy or counselling, within the past 6 months~* Patients experiencing severe melancholia, neurovegetative symptoms or current suicidality necessitating acute hospitalisation or intensive psychiatric treatment.~* Patients with psychotic symptoms or past history of severe mental illness including schizophrenia, and bipolar disorder.~* Use of any form of estrogen, progestin or androgen as hormonal therapy, or antiandrogen including tibolone or use of phytoestrogen supplements as powder or tablet~* Pregnancy / Lactation~* Smoking cigarettes and other nicotine products.~* illicit drug use and more than 3 standard drinks per day

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Tibolone (Type: EXPERIMENTAL): Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial.
- Escitalopram (Type: ACTIVE_COMPARATOR): 10mg of escitalopram will be taken by participants daily for the duration of the 12 week trial period.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo arm containing sweetener has been approved and will be used as placebo arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).